Here's Why Celgene Boosted Its Bet on Forma Therapeutics

Celgene (CELG) recently expanded its collaboration with emerging biotech Forma Therapeutics, but it's far from the only heavyweight teamed up with the company. Forma's collaborators include Novartis (NVS), Lilly (LLY), and Johnson & Johnson (JNJ) too.

Apr 1, 2014 at 8:41PM

Celgene (NASDAQ:CELG) is one of the most prolific dealmakers in the biotech industry. It's increasingly building out a pre-clinical pipeline that is tightly tied to therapies targeting enzymes, proteins, and their inter-relationships.

The company's latest move is to cozy up to Forma Therapeutics, a six-year-old Massachusetts biotechnology company that's building one of the most robust drug discovery engines in the industry.

CELG Chart

CELG data by YCharts

Who is Forma Therapeuticas?
Former Novartis (NYSE:NVS) dealmaker Steven Tregay and three members of the Broad Institute launched Forma Therapeutics in 2008. Their goal was -- and remains -- simple: to leverage the latest advances in genetic, chemical, and analytic insight to discover and develop drugs more quickly.

Accomplishing that goal, however, is likely to be anything but simple. For Forma to succeed, it needs to toss aside decades of deeply ingrained R&D practice and process, and embrace systems that can evaluate disease targets in parallel.

That complexity is one of the reasons a variety of industry heavyweights have linked up with Forma rather than tear down and reimagine their own R&D departments.

The equity investment arms of Novartis and Eli Lilly were among Forma's earliest backers, and financing from Novartis, Lilly (NYSE:LLY), Cubist, and Roche's (NASDAQOTH:RHHBY) Genentech has helped Forma build a substantial R&D team focused on tumor metabolism, epigenetics, protein homeostasis, and protein-to-protein interactions. Those are all emerging -- and mostly commercially unproven -- areas of research.

In addition to seed money, Novartis struck a deal with Forma to develop a protein-to-protein interaction-based cancer drug. Anti-viral leader Cubist and Japanese drugmaker Eisai have also provided upfront cash tied to collaboration deals.

Johnson & Johnson (NYSE:JNJ) teamed up with Forma in 2012 to develop tumor metabolism therapies in a deal that could eventually be worth up to $700 million to Forma, and Boehringer could pay Forma up to $750 million in potential milestones if its collaboration works out as hoped. Roche's Genentech has nabbed exclusive global rights to a Forma pre-clinical drug that starves tumors by blocking cancer cell metabolism, too.

Why is Celgene interested?
Celgene has been spending big money on collaborations with epigenetics-focused emerging biotechnology companies. Those companies are studying why cells can look similar yet behave differently -- in the process causing or contributing to a variety of cancer and autoimmune disease.

Those are important markets for Celgene, given that it markets the highly successful blockbuster myeloma drug Revlimid, and the recently approved psoriatic arthritis drug Otezla.

Celgene first agreed to collaborate with Forma last April on protein homeostasis cancer targets. That's an intriguing area for research, since disruptions in normal cell function, such as protein folding and degradation, may be tied to cancer. As part of that agreement, Celgene agreed to pay Forma up to $200 million, including upfront money and milestones.

Celgene is apparently happy with the early results. The deal with Forma this week is much larger and cuts across a wider range of disease targets. Overall, the agreement could be worth up to $600 million for Forma, including a $225 million upfront payment and potential milestones. Celgene also agreed to pay mid- and late-stage development costs. Additionally, the deal includes a provision that would allow Celgene to acquire Forma under certain circumstances.

Fool-worthy final thoughts
Celgene's collaborations -- this one included -- are primarily with companies offering pre-clinical ideas, rather than in-clinic compounds.

That means all of Forma's partners, including Novartis, Lilly, Roche, Johnson, and Celgene, will have to wait years before learning if their collaborations with Forma pay off. In the meantime, however, each gets access to a promising new approach to drug discovery in exchange for upfront payments that are relatively small compared with what it would cost to build such programs in-house. In that respect, Celgene appears to have an attractive call option on Forma. 

Here's 1 idea that may pay off more quickly
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but also your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.


Todd Campbell owns Celgene. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Celgene and Johnson & Johnson and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information